Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs

Lars Fruergaard Jorgensen holding a microphone in one hand and paper flashcards in the other hand (Credit: MOHAMMED BADRA—AFP/Getty Images)

Novo Nordisk’s sales have skyrocketed with the popularity of its weight-loss and obesity drugs. The Danish drugmaker’s sales in those two categories were up 36% in the nine months of 2023, to $22 billion. 

But as demand has outstripped supply, with millions of potential patients yet to be served, the Danish pharma giant is considering creative ways to address the market.